Exactly!!
If we had ploughed money into R&D on hernia and breast sling we wouldn’t have been able to get as many sales people into hospitals and our sales figures and imminent profits would be set right back.
I’m not so sure hernia is going to contribute that much anyway.
The setback with the DFU trial is frustrating - that’s where the cash will really start rolling in when it’s complete.
But better to get the protocol issues sorted than to have pushed on and had it rejected because of inconsistencies between sites.
Meanwhile everything else is going along swimmingly and set to remain in hyper growth for years to come. Synpath will ensure that happens once we get over the finishing line in the states. Should coincide roughly with completion of BARDA trials and provide a double boon to sales.
PNV - Banter and General Comments, page-11108
-
- There are more pages in this discussion • 1,107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
0.110(4.74%) |
Mkt cap ! $1.677B | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.45 | $2.38 | $2.896M | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.43 | 9997 | 4 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |